Metabolon, a developer of biochemical profiling technology, has raised $15 million in a new round of financing, the company disclosed earlier this week.
It wasn't immediately clear how Durham, NC-based Metabolon plans to use the funds. The company recently announced a collaboration with Richmond, VA-based Global Genomics Group (G3), focused on biomarkers and drug targets for cardiovascular diseases, according to the Triangle Business Journal.
It also has a recently signed marketing agreement with Bostwick Laboratories of Uniondale, NY, the Business Journal reported. Bostwick is a full-service lab specializing in uropathology and urological cancers such as prostate cancer.
Investors include Fletcher Spaght Ventures, Sevin Rosen Funds and Syngenta Ventures.
Metabolon gets its name from metabolomics, the study of the small-molecule signatures generated by metabolic processes. The company advertises its biochemical profiling platform as useful in a wide range of diagnostics.